Print
|
Close
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
Active:
No
Cancer Type:
Multiple Myeloma
Plasma cell neoplasm
NCT ID:
NCT05347485
Trial Phases:
Phase II
Protocol IDs:
CR109014 (primary)
NCI-2022-03839
68284528MMY2005
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Janssen Scientific Affairs, LLC
NCI Full Details:
http://clinicaltrials.gov/show/NCT05347485
Summary
The purpose of this study is to evaluate the efficacy and safety of cilta-cel
out-of-specification (OOS).
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.